We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/7/2019 08:05 | recent director appointments are impressive and appear very ambitious. looks like the company really thinks it can grow significantly. IMHO. | mfhmfh | |
22/7/2019 07:28 | Market certainly seems to like it! | bermudashorts | |
22/7/2019 07:01 | Looks like the group generated £6m of cash in H1 (8m v 2m at ye). Annualised that is circa 12m. So ten times cash generation and growing at 30%. Could be good value. NB I have not checked whether there is half year bias in cash generation. | sidam | |
22/7/2019 06:21 | Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented:"Following a strong start to the year, we are pleased to have continued performing above expectations, and again upgrade guidance for FY19. Not only have we delivered growth as a profitable and cash-generative business, but we have also strengthened both the management team and the Board. Ergomed is in robust shape, and we are committed to our strategy of focusing on the opportunities in specialised CRO services and pharmacovigilance." | epicsurf | |
22/7/2019 06:15 | Strong trading and forward-looking order book The strong trading seen across the Company at the start of the year continued throughout the first half of 2019. Unaudited revenues for H1 2019 are expected to be approximately £35.0 million (H1 2018: £25.7 million), an increase of 36%, with CRO revenues increasing 40% from £13.6 million to £19.0 million and PV revenues increasing 32% from £12.1 million to £16.0 million. Sales of new business for H1 2019 are strong, with the largest increase being in the CRO business. At H1 2019 the Company continues to be debt-free and is expected to report net positive cash balances of around £8 million. The Company has now fully adopted IFRS 15 (revenue recognition) with effect from 1 January 2019 and comparative periods, therefore where relevant all figures are stated on an IFRS 15 basis. | epicsurf | |
19/7/2019 18:03 | Looks like a ramping scam. Lemmings and mushrooms only. | ken chung | |
17/7/2019 17:25 | Is the company being acquired??? | ih_198062 | |
17/7/2019 16:26 | Whats up with the very large block trades on 7/16 and 7/17? 7/16 had 4 large blocks: 970K, 900K, 105K and 103K 7/17 had 4 large blocks: 100K, 55K x2 and 50K | ih_198062 | |
10/7/2019 11:34 | another heavyweight board appointment announced today IMHO. direction of the company seems clear. | mfhmfh | |
26/6/2019 11:25 | top-up opportunity especially as the Executive Chairman purchased 200,000 shares at a price of 303p. IMHO. | mfhmfh | |
25/6/2019 08:26 | heavy buying by new CFO recently and now by the Executive Chairman. | mfhmfh | |
25/6/2019 07:31 | I wonder who bought the other 290,000 shares at 303p yesterday and who sold the 490,000 shares. | ih_433513 | |
25/6/2019 06:20 | Ergomed, a company focused on providing specialised services to the pharmaceutical industry, announces that on 24 June 2019, Dr Miroslav Reljanovic, Exe | epicsurf | |
24/6/2019 19:04 | I had assumed that the recent perkiness in the Ergo share price was due to them shifting away from the co-development model and just focusing on the pharmaceutical services parts of the business. Unfortunately I couldn't get to the AGM earlier this year, if I had gone, I had lots of questions about that. If they end up making the transition completely, I wonder if they are contemplating selling the future royalty streams from the current co-development portfolio? I suspect there would be plenty of potential buyers. | timbo003 | |
24/6/2019 18:39 | Been watching cel-sci share price up around 10% today . Ergomed is a new share purchase for me In at £2.34 so happy with uptick | epicsurf | |
24/6/2019 15:26 | Interesting thanks sushifishman. Have to admit that I've always been a bit sceptical of Ergomed's co-development partnerships but will be very happy to eat humble pie if Multikine comes off. | bermudashorts | |
13/6/2019 09:15 | yep - over £250k in total | bermudashorts | |
13/6/2019 08:41 | wow - new CFO bought another 64,000 shares at 270 pence. That's £172,800.00. He must be confident. | mfhmfh | |
10/6/2019 08:53 | good to see newly appointed CFO purchasing 36,000 shares at 241.5 pence. That's nearly £87,000 spent at near all time highs. | mfhmfh | |
04/6/2019 08:37 | Yes, seems like a good fit. | bermudashorts | |
04/6/2019 08:15 | good appointment of CFO today IMHO. | mfhmfh | |
16/5/2019 08:51 | Harwood Capital LLP continue to increase their stake. hopefully a positive. | mfhmfh | |
16/5/2019 08:50 | great announcement today IMHO: 'As a result, Ergomed now expects revenue and EBITDA for the year ending 31 December 2019 to be materially above current market expectations.' | mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions